CTLA4 and neoplasm: This treatment regimen, which involves an Fc-enhanced anti-CTLA-4 antibody (BOT) and an anti-PD-1 antibody (BAL), led to an unusual “inside-out” (serosa-to-mucosa) pattern of tumor regression.